|
Name |
1-Heptacosanol
|
| Molecular Formula | C27H56O | |
| IUPAC Name* |
heptacosan-1-ol
|
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCCCCO
|
|
| InChI |
InChI=1S/C27H56O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28/h28H,2-27H2,1H3
|
|
| InChIKey |
ULCZGKYHRYJXAU-UHFFFAOYSA-N
|
|
| Synonyms |
1-Heptacosanol; Heptacosanol; 2004-39-9; heptacosan-1-ol; VO02AJN4KP; NSC-53829; Heptacosanol (VAN); UNII-VO02AJN4KP; n-heptacosanol; EINECS 217-906-9; MFCD00057822; NSC 53829; 1-Heptacosanol, >=98%; SCHEMBL15346; Heptacosanol, heptacosan-1-ol; DTXSID20173861; CHEBI:133981; NSC53829; LMFA05000456; ZINC62238216; FT-0752010; J-012973; Q4545780
|
|
| CAS | 2004-39-9 | |
| PubChem CID | 74822 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 396.7 | ALogp: | 13.3 |
| HBD: | 1 | HBA: | 1 |
| Rotatable Bonds: | 25 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 20.2 | Aromatic Rings: | 0 |
| Heavy Atoms: | 28 | QED Weighted: | 0.128 |
| Caco-2 Permeability: | -5.27 | MDCK Permeability: | 0.00000360 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.04 |
| 30% Bioavailability (F30%): | 0.999 |
| Blood-Brain-Barrier Penetration (BBB): | 0.004 | Plasma Protein Binding (PPB): | 98.39% |
| Volume Distribution (VD): | 4.377 | Fu: | 1.01% |
| CYP1A2-inhibitor: | 0.051 | CYP1A2-substrate: | 0.137 |
| CYP2C19-inhibitor: | 0.111 | CYP2C19-substrate: | 0.045 |
| CYP2C9-inhibitor: | 0.025 | CYP2C9-substrate: | 0.971 |
| CYP2D6-inhibitor: | 0.102 | CYP2D6-substrate: | 0.015 |
| CYP3A4-inhibitor: | 0.138 | CYP3A4-substrate: | 0.013 |
| Clearance (CL): | 4.901 | Half-life (T1/2): | 0.02 |
| hERG Blockers: | 0.51 | Human Hepatotoxicity (H-HT): | 0.006 |
| Drug-inuced Liver Injury (DILI): | 0.208 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.008 | Maximum Recommended Daily Dose: | 0.018 |
| Skin Sensitization: | 0.978 | Carcinogencity: | 0.019 |
| Eye Corrosion: | 0.996 | Eye Irritation: | 0.916 |
| Respiratory Toxicity: | 0.351 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000359 | ![]() |
0.890 | D00AOJ | ![]() |
0.817 | ||
| ENC001238 | ![]() |
0.885 | D07ILQ | ![]() |
0.479 | ||
| ENC000435 | ![]() |
0.885 | D00STJ | ![]() |
0.463 | ||
| ENC000436 | ![]() |
0.856 | D00FGR | ![]() |
0.414 | ||
| ENC000401 | ![]() |
0.851 | D0Z5SM | ![]() |
0.388 | ||
| ENC000443 | ![]() |
0.828 | D0O1PH | ![]() |
0.370 | ||
| ENC000449 | ![]() |
0.817 | D05ZPL | ![]() |
0.333 | ||
| ENC000434 | ![]() |
0.816 | D05ATI | ![]() |
0.330 | ||
| ENC001125 | ![]() |
0.804 | D01NTX | ![]() |
0.321 | ||
| ENC000437 | ![]() |
0.802 | D0Z1QC | ![]() |
0.319 | ||